A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

Francis Giles; Srdan Verstovsek; Stefan Faderl; Norbert Vey; Judy Karp; Gail Roboz; Khuda Dan Khan; Maureen Cooper; Syed Fazl Ali Bilgrami; Augustin Ferrant; Simon Daenen; Verena Karsten; Ann Cahill; Maher Albitar; Hagop Kantarjian; Susan O'Brien; Eric Feldman

doi:10.1016/j.leukres.2006.02.019

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

Francis Giles^*, Srdan Verstovsek, Stefan Faderl, Norbert Vey, Judy Karp, Gail Roboz, Khuda Dan Khan, Maureen Cooper, Syed Fazl Ali Bilgrami, Augustin Ferrant, Simon Daenen, Verena Karsten, Ann Cahill, Maher Albitar, Hagop Kantarjian, Susan O'Brien, Eric Feldman

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

25 Scopus citations

Abstract

Cloretazine® (VNP40101M) is a sulfonylhydrazine alkylating agent with significant anti-leukemia activity. A multicenter phase II study of cloretazine was conducted in patients with first relapse of acute myeloid leukemia (AML) following an initial complete remission (CR) of less than 12 months. Cloretazine was given as a single intravenous infusion at a dose of 600 mg/m². Fifty-three patients (median age 62 years (18-84), 41 of 44 (93%) evaluable with intermediate or high risk cytogenetics, 32 (60%) with initial CR durations ≤6 months) were treated on study. Two patients (4%) achieved a second CR. Five (9%) patients died within 30 days of receiving cloretazine therapy. Median overall survival (2.3 months) in the study cohort was directly comparable to that of 233 matched patients treated with other single agents. The study cloretazine regimen had minimal activity in a very high risk subset of patients with relapsed AML.

Original language	English (US)
Pages (from-to)	1591-1595
Number of pages	5
Journal	Leukemia Research
Volume	30
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2006.02.019
State	Published - Dec 2006

Keywords

90CE
Alkylating
Relapsed AML
Sulfonylhydrazine
VNP40101M

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2006.02.019

Cite this

Giles, F., Verstovsek, S., Faderl, S., Vey, N., Karp, J., Roboz, G., Khan, K. D., Cooper, M., Bilgrami, S. F. A., Ferrant, A., Daenen, S., Karsten, V., Cahill, A., Albitar, M., Kantarjian, H., O'Brien, S., & Feldman, E. (2006). A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia Research, 30(12), 1591-1595. https://doi.org/10.1016/j.leukres.2006.02.019

@article{4c90fdd262a64eefad2a9fc6a373904b,

title = "A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia",

abstract = "Cloretazine{\textregistered} (VNP40101M) is a sulfonylhydrazine alkylating agent with significant anti-leukemia activity. A multicenter phase II study of cloretazine was conducted in patients with first relapse of acute myeloid leukemia (AML) following an initial complete remission (CR) of less than 12 months. Cloretazine was given as a single intravenous infusion at a dose of 600 mg/m2. Fifty-three patients (median age 62 years (18-84), 41 of 44 (93%) evaluable with intermediate or high risk cytogenetics, 32 (60%) with initial CR durations ≤6 months) were treated on study. Two patients (4%) achieved a second CR. Five (9%) patients died within 30 days of receiving cloretazine therapy. Median overall survival (2.3 months) in the study cohort was directly comparable to that of 233 matched patients treated with other single agents. The study cloretazine regimen had minimal activity in a very high risk subset of patients with relapsed AML.",

keywords = "90CE, Alkylating, Relapsed AML, Sulfonylhydrazine, VNP40101M",

author = "Francis Giles and Srdan Verstovsek and Stefan Faderl and Norbert Vey and Judy Karp and Gail Roboz and Khan, {Khuda Dan} and Maureen Cooper and Bilgrami, {Syed Fazl Ali} and Augustin Ferrant and Simon Daenen and Verena Karsten and Ann Cahill and Maher Albitar and Hagop Kantarjian and Susan O'Brien and Eric Feldman",

year = "2006",

month = dec,

doi = "10.1016/j.leukres.2006.02.019",

language = "English (US)",

volume = "30",

pages = "1591--1595",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "12",

}

Giles, F, Verstovsek, S, Faderl, S, Vey, N, Karp, J, Roboz, G, Khan, KD, Cooper, M, Bilgrami, SFA, Ferrant, A, Daenen, S, Karsten, V, Cahill, A, Albitar, M, Kantarjian, H, O'Brien, S & Feldman, E 2006, 'A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia', Leukemia Research, vol. 30, no. 12, pp. 1591-1595. https://doi.org/10.1016/j.leukres.2006.02.019

TY - JOUR

T1 - A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

AU - Giles, Francis

AU - Verstovsek, Srdan

AU - Faderl, Stefan

AU - Vey, Norbert

AU - Karp, Judy

AU - Roboz, Gail

AU - Khan, Khuda Dan

AU - Cooper, Maureen

AU - Bilgrami, Syed Fazl Ali

AU - Ferrant, Augustin

AU - Daenen, Simon

AU - Karsten, Verena

AU - Cahill, Ann

AU - Albitar, Maher

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Feldman, Eric

PY - 2006/12

Y1 - 2006/12

N2 - Cloretazine® (VNP40101M) is a sulfonylhydrazine alkylating agent with significant anti-leukemia activity. A multicenter phase II study of cloretazine was conducted in patients with first relapse of acute myeloid leukemia (AML) following an initial complete remission (CR) of less than 12 months. Cloretazine was given as a single intravenous infusion at a dose of 600 mg/m2. Fifty-three patients (median age 62 years (18-84), 41 of 44 (93%) evaluable with intermediate or high risk cytogenetics, 32 (60%) with initial CR durations ≤6 months) were treated on study. Two patients (4%) achieved a second CR. Five (9%) patients died within 30 days of receiving cloretazine therapy. Median overall survival (2.3 months) in the study cohort was directly comparable to that of 233 matched patients treated with other single agents. The study cloretazine regimen had minimal activity in a very high risk subset of patients with relapsed AML.

AB - Cloretazine® (VNP40101M) is a sulfonylhydrazine alkylating agent with significant anti-leukemia activity. A multicenter phase II study of cloretazine was conducted in patients with first relapse of acute myeloid leukemia (AML) following an initial complete remission (CR) of less than 12 months. Cloretazine was given as a single intravenous infusion at a dose of 600 mg/m2. Fifty-three patients (median age 62 years (18-84), 41 of 44 (93%) evaluable with intermediate or high risk cytogenetics, 32 (60%) with initial CR durations ≤6 months) were treated on study. Two patients (4%) achieved a second CR. Five (9%) patients died within 30 days of receiving cloretazine therapy. Median overall survival (2.3 months) in the study cohort was directly comparable to that of 233 matched patients treated with other single agents. The study cloretazine regimen had minimal activity in a very high risk subset of patients with relapsed AML.

KW - 90CE

KW - Alkylating

KW - Relapsed AML

KW - Sulfonylhydrazine

KW - VNP40101M

UR - http://www.scopus.com/inward/record.url?scp=33750022018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750022018&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.02.019

DO - 10.1016/j.leukres.2006.02.019

M3 - Letter

C2 - 16574225

AN - SCOPUS:33750022018

SN - 0145-2126

VL - 30

SP - 1591

EP - 1595

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this